Study of Tenecteplase Versus Alteplase for Thrombolysis (Clot Dissolving) in Acute Ischemic Stroke

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1050 participants.

Also called NCT01949948

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,050 participants (enrolled count) (from the registry)
Sponsor
Lars Thomassen (from the registry)
Registry
  • NCT NCT01949948
Other papers using this trial's data
  • Association between blood pressure and outcome in patients with acute ischemic stroke treated with alteplase Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2026-01 DOI, PubMed 41360194
  • Clinical outcomes and safety profile of Tenecteplase in wake-up stroke Acta neurologica Scandinavica, 2020-11 DOI, PubMed 32511749
  • Safety and Outcomes of Tenecteplase in Moderate and Severe Ischemic Stroke Stroke, 2019-05 DOI, PubMed 31009339
  • Sex differences in the Norwegian Tenecteplase Trial (NOR-TEST) European journal of neurology, 2022-02 DOI, PubMed 34564893
  • Tenecteplase Versus Alteplase Between 3 and 4.5 Hours in Low National Institutes of Health Stroke Scale Stroke, 2019-02 DOI, PubMed 30602354
  • Tenecteplase versus alteplase after acute ischemic stroke at high age International journal of stroke : official journal of the International Stroke Society, 2021-04 DOI, PubMed 32631157
  • Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial The Lancet. Neurology, 2017-10 DOI, PubMed 28780236

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Norway (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01949948. Randomized; double masking; primary purpose treatment. Start 2012-09 (actual); primary completion 2016-12-31 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of Tenecteplase Versus Alteplase for Thrombolysis (Clot Dissolving) in Acute Ischemic Stroke
Acronym
NOR-TEST
Intervention (Drug)
Tenecteplase
Intervention (Drug)
Alteplase
Lead sponsor
Lars Thomassen (class: other)
Collaborator
The Research Council of Norway (class: other)

Record details

Record id
cardio:ct-nct01949948
Content hash
f9d1dbfcd64b3e6ce09441fd9caf60e5edb87553d524c54d396f6e58d30cdb79